Agreement with EirGenix Inc. grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment of HER2-positive early breast cancer / metastatic breast cancer.

Obesity drugs are advancing with over 100 drugs in development. New treatments combining GLP-1 with other hormones are being developed.

As AI transforms health care, clear frameworks are needed to ensure ethical, equitable, and effective use. The DI PRN of the ACCP urges responsible implementation and improved AI literacy to empower clinicians and patients.

Biosimilars are rapidly transforming the U.S. pharmaceutical market amid rising healthcare costs and a shift in interchangeability policy. Market competition is intensifying, with some biosimilars offering wholesale and ASP discounts, signaling significant cost savings and ultimately broader adoption.